Drugs / AIV001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04827875 | Jun 2021 → Dec 2022 | keloid | AiViva BioPharma, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04470726 | Aug 2020 → Jun 2023 | nodular basal cell carcinoma | AiViva BioPharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03639883 | Nov 2018 → Dec 2019 | — | AiViva BioPharma, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03883945 Comparator | Jul 2021 → Jul 2022 | rosacea | AiViva BioPharma, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIV001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04827875 ↗ |
| Known as | axitinib | “AIV001 (axitinib) has been formulated to provide focal disease-modifying therapy for patients with nonmelanoma skin cancer (NMSC) of the basal cell carcinoma (BCC) subtype.” NCT04470726 ↗1“AIV001 (axitinib) has been formulated to provide focal disease-modifying therapy for patients undergoing surgical procedures where scar formation will occur.” NCT04827875 ↗ |
| Route | Other | “AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection” NCT04470726 ↗ |